查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1517636

維生素 D 治療市場 - 給藥途徑（口服、腸胃外）、類型（非處方藥、處方）、應用（骨質疏鬆症、佝僂病、肌肉無力）、年齡層（兒童、成人、老年人）、配銷通路、全球預測（2024 - 2032 年） ）

Vitamin D Therapy Market - Route of Administration (Oral, Parenteral), Type (OTC, Prescription), Application (Osteoporosis, Rickets, Muscle Weakness), Age Group (Children, Adults, Geriatric), Distribution Channel, Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 187 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在全球範圍內日益成長的採用和需求的推動下，維生素 D 療法市場規模預計 2024 年至 2032 年間複合年成長率為 11.4%。消費者和醫療保健專業人員越來越認知到維生素 D 在維持整體健康（包括骨骼健康、免疫功能和心血管健康）方面的重要作用。隨著越來越多的研究強調補充維生素 D 在預防慢性疾病方面的潛在益處，補充劑和療法也隨之大量引入。例如，2024 年2 月，Cadila Pharmaceuticals 推出了一種用於治療維生素D 缺乏症的膽鈣化醇水劑製劑，與傳統的油性製劑相比，該製劑表現出優異的藥物動力學(PK)和藥效學(PD)。

老年人口的增加，特別是在北美和歐洲等已開發地區，也推動了市場的成長。由於皮膚合成和飲食攝取量減少，老年人也容易缺乏維生素 D，導致補充維生素 D 的需求增加。各年齡層的生活方式的改變，包括室內久坐習慣和有限的陽光照射，將進一步推動產業擴張。

維生素D治療產業分為給藥途徑、類型、應用、年齡層、配銷通路和地區。

根據類型，由於人們越來越認知到維生素 D 缺乏症是全球重大的公共衛生問題，因此到 2032 年，處方藥領域的市場價值將出現顯著的複合年成長率。醫療保健提供者擴大開出維生素 D 補充劑處方，作為對確診缺乏維生素 D 或缺乏維生素 D 的高風險患者的治療干預措施的一部分。處方強度維生素 D 配方可根據患者個別需求進行精確劑量調整，以確保有效管理維生素 D 缺乏相關疾病，例如骨質疏鬆症、低血鈣症和某些自體免疫疾病。

由於維生素 D 在改善皮膚健康和免疫功能方面發揮重要作用，皮膚病應用領域的維生素 D 治療市場預計將在 2024 年至 2032 年期間產生收入。維生素 D 有助於調節免疫反應並促進皮膚細胞生長和修復，使其特別有利於管理各種皮膚狀況。患有慢性皮膚病的人通常會因陽光照射有限或皮膚屏障功能受損而導致維生素 D 合成受損，導致他們更加依賴補充劑來維持最佳水平。

到 2032 年，亞太地區維生素 D 治療產業將錄得可觀的成長速度。這提高了醫療保健專業人員和消費者對補充維生素 D 重要性的認知。各種維生素 D 產品的供應，包括針對地區飲食偏好和醫療保健需求量身定做的強化食品和補充劑，也推動了市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 人們對維生素 D 缺乏症的認知不斷增強
      • 人口老化加劇
      • 非處方藥的供應
    • 產業陷阱與挑戰
      • 與治療相關的副作用
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按管理途徑，2021 - 2032 年

  • 主要趨勢
  • 口服
  • 注射用

第 6 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 非處方藥
  • 處方藥

第 7 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 骨質疏鬆症
  • 肌肉無力
  • 疳
  • 自體免疫疾病
  • 皮膚病
  • 其他應用

第 8 章：市場估計與預測：按年齡分類，2021 - 2032

  • 主要趨勢
  • 老年科
  • 成年人
  • 孩子們

第 9 章：市場估計與預測：按配銷通路，2021 - 2032

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 11 章：公司簡介

  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Atrium Innovations
  • Biotics Research Corporation
  • Cadila Healthcare Ltd.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Ortho Molecular Products
  • Pfizer, Inc.
  • Sanofi
簡介目錄
Product Code: 9170

Vitamin D Therapy Market size is anticipated to register 11.4% CAGR between 2024 and 2032, driven by the increasing adoption and demand worldwide. There is a growing awareness among consumers and healthcare professionals about the essential role of vitamin D in maintaining overall health, including bone health, immune function, and cardiovascular health. As more research highlights the potential benefits of vitamin D supplementation in preventing chronic diseases, there has been significant introduction of supplements and therapies. For instance, in February 2024, Cadila Pharmaceuticals launched an aqueous formulation of cholecalciferol for the treatment of vitamin D deficiency for exhibiting superior pharmacokinetics (PK) and pharmacodynamics (PD) compared to conventional oil-based formulations.

Rising geriatric population, particularly in developed regions like North America and Europe, is also fueling the market growth. Older adults are also susceptible to vitamin D deficiency on account of reduced skin synthesis and dietary intake, leading to an increased need for supplementation. Lifestyle changes, including indoor sedentary habits and limited sun exposure, across various age groups, will further drive the industry expansion.

The vitamin D therapy industry is divided into route of administration, type, application, age group, distribution channel, and region.

Based on type, the market value from the prescription drugs segment will witness notable CAGR through 2032 due to the rising recognition of vitamin D deficiency as a significant public health concern worldwide. Healthcare providers are increasingly prescribing vitamin D supplements as part of therapeutic interventions for patients with diagnosed deficiencies or at high risk of deficiency. Prescription-strength vitamin D formulations allow precise dosing tailored to individual patient needs for ensuring effective management of deficiency-related conditions, such as osteoporosis, hypocalcemia, and certain autoimmune disorders.

Vitamin D therapy market from the skin diseases application segment is slated to generate revenue during 2024-2032 owing to the essential role to improve skin health and immune function. Vitamin D helps in regulating the immune response and promoting skin cell growth and repair, making it particularly beneficial in the management of various skin conditions. Individuals with chronic skin diseases often have impaired vitamin D synthesis due to limited sun exposure or compromised skin barrier function, leading to the increased reliance on supplements to maintain optimal levels.

Asia Pacific vitamin D therapy industry will record decent growth rate through 2032. This is attributed to the increasing prevalence of vitamin D deficiency among the regional population due to factors, such as indoor lifestyles, limited sun exposure, and dietary habits. This has led to heightened awareness among healthcare professionals and consumers about the importance of vitamin D supplementation. The availability of a diverse range of vitamin D products, including fortified foods and supplements, tailored to regional dietary preferences and healthcare needs, is also driving the market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing awareness of vitamin D deficiency
      • 3.2.1.2 Increasing ageing population
      • 3.2.1.3 Availability of OTC drugs
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects associated with therapy
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Oral
  • 5.3 Parenteral

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 OTC drugs
  • 6.3 Prescription drugs

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Osteoporosis
  • 7.3 Muscle weakness
  • 7.4 Rickets
  • 7.5 Autoimmune disorders
  • 7.6 Skin diseases
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Geriatric
  • 8.3 Adults
  • 8.4 Children

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Abbott Laboratories
  • 11.2 Alkem Laboratories Ltd.
  • 11.3 Atrium Innovations
  • 11.4 Biotics Research Corporation
  • 11.5 Cadila Healthcare Ltd.
  • 11.6 GlaxoSmithKline plc
  • 11.7 Merck & Co. Inc.
  • 11.8 Ortho Molecular Products
  • 11.9 Pfizer, Inc.
  • 11.10 Sanofi